Recommendations for the Management of Drug–Drug Interactions Between the <scp>COVID</scp> ‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications-Reference-Cited by-同舟云学术

Recommendations for the Management of Drug–Drug Interactions Between the COVID ‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications

Published:2022-06-07 Issue:6 Volume:112 Page:1191-1200
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Marzolini Catia¹²,Kuritzkes Daniel R.³,Marra Fiona²⁴,Boyle Alison²⁴,Gibbons Sara²,Flexner Charles⁵,Pozniak Anton⁶⁷,Boffito Marta⁶,Waters Laura⁸,Burger David⁹¹⁰,Back David J.²,Khoo Saye²

Affiliation:

1. Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research University Hospital of Basel and University of Basel Basel Switzerland

2. Department of Molecular and Clinical Pharmacology University of Liverpool Liverpool UK

3. Division of Infectious Diseases, Brigham and Women's Hospital Harvard Medical School Boston MA USA

4. Department of Pharmacy National Health Service Greater Glasgow and Clyde Glasgow UK

5. Divisions of Clinical Pharmacology and Infectious Diseases, School of Medicine and Bloomberg School of Public Health Johns Hopkins University Baltimore MD USA

6. Chelsea and Westminster Hospital National Health Service Foundation Trust London UK

7. London School of Hygiene and Tropical Medicine London UK

8. Mortimer Market Centre, Central and North West London National Health Service Foundation Trust London UK

9. Department of Pharmacy Radboud University Medical Center Nijmegen The Netherlands

10. Global DDI Solutions Utrecht The Netherlands

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2646

Reference55 articles.

1. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

2. Twenty years of boosting antiretroviral agents

3. Paxlovid Summary of Product Information Accessed February 1 2022.

4. US Food and Drug Administration.Fact sheet for healthcare providers: emergency use authorization for Paxlovid Accessed May 5 2022.

5. Concentration effect relationship of CYP3A inhibition by ritonavir in humans

Cited by 162 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiviral agents and therapeutics against respiratory viruses;Expert Opinion on Investigational Drugs;2024-09-08

2. Design of novel and highly selective SARS-CoV-2 main protease inhibitors;Antimicrobial Agents and Chemotherapy;2024-09-03

3. An overview of the development of pharmacotherapeutics targeting SARS-CoV-2;Drug Discovery Today;2024-09

4. Prevalence of Potential Drug Interactions With Direct-Acting Antivirals for COVID-19 Among Hospitalized Patients;Clinical Therapeutics;2024-09

5. Inhibition of P-Glycoprotein Asymmetrically Alters the In Vivo Exposure Profile of SGC003F: A Novel Guanylate Cyclase Stimulator;Pharmaceuticals;2024-08-29